May 11, 2017

Biomarker for Clinical Trials in Angelman Syndrome

ASF-funded Research Identifies Biomarker for Clinical Trials ASF-funded research published in the Journal of Neurodevelopmental Disorders has identified that delta—a frequency of brain rhythms identifiable by EEG scans—can serve as a reliable biomarker for pre-clinical and clinical trials in Angelman syndrome. The research team, […]

Read more
Ovid Therapeutics logo
September 9, 2016

Ovid Therapeutics Receives Orphan Drug Designation

Ovid Therapeutics, a privately held biopharmaceutical company based in New York City, announced that the U.S. Food and Drug Administration has granted orphan drug designation to OV101 for the treatment of patients with Angelman syndrome. See the press release. 

Read more